These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 4475428)

  • 1. Serum clofibrate concentrations in patients on continuous medication.
    Faed EM; McQueen EG
    Pharmacology; 1974; 12(3):144-51. PubMed ID: 4475428
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma concentrations and bioavailability of clofibrate after administration to human subjects.
    Chasseaud LF; Cooper AJ; Saggers VH
    J Clin Pharmacol; 1974 Jul; 14(7):382-6. PubMed ID: 4845394
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 4. Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
    Oster P; Schlierf G; Lang PD; Mordasini R; Vollmar J
    Pharmatherapeutica; 1985; 4(5):267-77. PubMed ID: 4070320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans.
    Taylor T; Chasseaud LF
    J Pharm Sci; 1977 Nov; 66(11):1638-9. PubMed ID: 915750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay of clofibrate in human serum by gas chromatography.
    Karmen A; Haut H
    Biochem Med; 1975 Feb; 12(2):154-61. PubMed ID: 1137577
    [No Abstract]   [Full Text] [Related]  

  • 7. [A quantitative gaschromatographic method for the determination of p-chlorophenoxyisobutyric acid (clofibrinic acid) in human plasma (author's transl)].
    Häselbarth V
    Arzneimittelforschung; 1976; 26(11):2076-80. PubMed ID: 1037251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 9. [Gas chromatographic analysis of p-chlorphenoxy-isobutyric acid (clofibrate)].
    Knüchel F; Ochs H
    Arzneimittelforschung; 1974 Apr; 24(4):576-8. PubMed ID: 4408060
    [No Abstract]   [Full Text] [Related]  

  • 10. Clofibrate and enzymatic induction in man.
    Houin G; Tillement JP
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):150-4. PubMed ID: 649234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of clofibrate in patients with renal insufficiency.
    Viikari J; Anttila M; Kasanen A
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma half-life of clofibric acid in renal failure.
    Faed EM; McQueen EG
    Br J Clin Pharmacol; 1979 Apr; 7(4):407-10. PubMed ID: 444361
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.
    Männistö PT; Tuomisto J; Jounela A; Penttilä O
    Acta Pharmacol Toxicol (Copenh); 1975 Apr; 36(4):353-65. PubMed ID: 1093358
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioavailability of p-chlorophenoxyisobutyric acid (clofibrinic acid) after repeated doses of its calcium salt to humans.
    Taylor T; Chasseaud LF; Darragh A; O'Kelly DA
    Eur J Clin Pharmacol; 1978 Mar; 13(1):49-53. PubMed ID: 639833
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

  • 16. Disposition pharmacokinetics of bezafibrate in man.
    Abshagen U; Bablok W; Koch K; Lang PD; Schmidt HA; Senn M; Stork H
    Eur J Clin Pharmacol; 1979 Aug; 16(1):31-8. PubMed ID: 499297
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of long-term administration of Clofibrate Spofa on serum lipid level].
    Cagãnovă A; Cagăn S
    Cas Lek Cesk; 1972 Jun; 111(25):595-600. PubMed ID: 5036057
    [No Abstract]   [Full Text] [Related]  

  • 18. A gas chromatographic method for the determination of bezafibrate in serum and urine.
    Endele R
    J Chromatogr; 1978 Jul; 154(2):261-3. PubMed ID: 681474
    [No Abstract]   [Full Text] [Related]  

  • 19. [Serum gas chromatographic determination of hypolipemic agents derived from clofibric acid].
    Cailleux A; Allain P
    Therapie; 1976; 31(5):631-6. PubMed ID: 1013955
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of high-performance liquid chromatography to measure plasma concentrations of p-chlorophenoxyisobutric acid after administration of clofibrate to humans.
    Woodhouse RN; Cresswell DG; Chasseaud LF; Brodie RR
    J Chromatogr; 1977 Jul; 137(1):218-21. PubMed ID: 893585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.